HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC for EMERGENT BIOSOLUTIONS
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Disaster Planning/Emergencies DIS
Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY P HECHT | — |
| THOMAS PAUL LATHAM | — |
| FRANKLIN C PHIFER | — |
Budget/Appropriations BUD
Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY P HECHT | — |
| THOMAS PAUL LATHAM | — |
| FRANKLIN C PHIFER | — |
Homeland Security HOM
Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY P HECHT | — |
| THOMAS PAUL LATHAM | — |
| FRANKLIN C PHIFER | — |
Health Issues HCR
Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY P HECHT | — |
| THOMAS PAUL LATHAM | — |
| FRANKLIN C PHIFER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.